Drugs / perillyl alcohol
perillyl alcohol
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00022425 | Jun 2001 → ? | breast cancer | The Cleveland Clinic | Unknown | No outcome recorded |
| Phase 1 | NCT00002862 | Oct 1996 → Apr 2001 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02704858 | Aug 2017 → Jul 2026 overdue | glioblastoma | Neonc Technologies, Inc. | Active not recruiting | Met primary |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT00608634 | May 2004 → Jun 2008 | precancerous condition | University of Arizona | Completed | Missed primary |
| Phase 2 | NCT00003769 | Feb 1999 → Jul 2001 | pancreatic adenocarcinoma | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT00003219 | May 1998 | breast cancer | University of Wisconsin, Madison | Completed | Missed primary |
| Phase 2 | NCT00003238 | Feb 1998 → Oct 2001 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | Neonc Technologies, Inc. | Results NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma neonc.com ↗ |
| 2025-03-31 | Neonc Technologies, Inc. | Regulatory NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 neonc.com ↗
Receiving the Rare Pediatric Disease Designation for NEO100 is a crucial step forward in our mission to develop effective treatments for children facing diffuse high-grade gliomas,” said Dr. Thomas Chen, CEO and Chief Science Officer of NeOnc Technologies Holdings, Inc. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | Neonc Technologies, Inc. | NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma neonc.com ↗ |
| 2025-03-31 | Neonc Technologies, Inc. | NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 neonc.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | perillyl alcohol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002862 ↗ |
| Known as | 4-isopropenylcyclo-hexenecarbinol | “Perillyl alcohol, also called p-metha1,7-diene-6-ol,or 4-isopropenylcyclo-hexenecarbinol, is a monoterpene, isolated from the essential oils of lavender, peppermint, spearmint,...” NCT02704858 ↗ |
| Known as | NSC 641066 | “A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer” NCT00003219 ↗ |
| Known as | p-metha1,7-diene-6-ol | “Perillyl alcohol, also called p-metha1,7-diene-6-ol,or 4-isopropenylcyclo-hexenecarbinol, is a monoterpene, isolated from the essential oils of lavender, peppermint, spearmint,...” NCT02704858 ↗ |
| Known as | POH | “Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.” NCT00608634 ↗2“Clinical trials performed in Brazil indicated that intranasal delivery of perillyl alcohol (POH) might be effective in this patient group.” PMID 33604574 ↗ Feb 2021 “Perillyl alcohol (POH) is a naturally occurring lipid with preclinical activity against mammary carcinomas.” PMID 17885756 ↗ Sep 2007 |
| Action | Inhibit | “A study revealed that H-Ras and K-Ras farnesylation were inhibited by perillyl alcohol.” NCT02704858 ↗ |
| Modality | Small molecule | “Perillyl alcohol, also called p-metha1,7-diene-6-ol,or 4-isopropenylcyclo-hexenecarbinol, is a monoterpene, isolated from the essential oils of lavender, peppermint, spearmint,...” NCT02704858 ↗ |
| Route | Oral | “Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined.” NCT00002862 ↗ |